Hypermethylation of gene promoters in hematological neoplasia

Hematological Oncology

Volumn 20, Issue 4, 2002, Pages 167-176

  Chim, C S ^a   Liang, R ^b   Kwong, Y L ^b  

^a QUEEN MARY S HOSPITAL   (United Kingdom)

^b University of Hong Kong ^*

Author keywords

CpG island; Hematologic malignancy; Hypermethylation; Tumour suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CALCITONIN; DNA METHYLTRANSFERASE; ESTROGEN RECEPTOR; GENE PRODUCT; HISTONE DEACETYLASE; PROTEIN HIC 1; PROTEIN P15; PROTEIN P16; PROTEIN P73; UNCLASSIFIED DRUG; UVOMORULIN;

BLOOD DISEASE; CHROMATIN STRUCTURE; CPG ISLAND; DEACETYLATION; DISEASE MARKER; DNA METHYLATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0036941943     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.694     Document Type: Review

References (50)

1. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nature Rev 2000; 1: 11-19.
2. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
3. Singal R, Ginder GD. DNA methylation. Blood 1999; 93: 4059-4070.
4. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMTI, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-1179.
5. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
6. Merlo A, Herman JG, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTSI in human cancers. Nature Med 1995; 1: 686-692.
7. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl A cad Sci U S A 1992; 89: 1827-1831.
8. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-9826.
9. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
10. Malinen T, Palotie A, Pakkala S, Peltonen L, Ruutu T, Jansson SE. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 1991; 77: 2435-2440.
11. Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood 1991; 77: 2431-2434.
12. Baylin SB, Fearon ER, Vogelstein B, et al. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 1987; 70: 412-417.
13. Ihalainen J, Pakkala S, Savolainen ER, Jansson SE, Palotie A. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. Leukemia 1993; 7: 263-267.
14. Leegwater PA, Lambooy LH, De Abreu RA, Bokkerink JP, van den Heuvel LP. DNA methylation patterns in the calcitonin gene region at first diagnosis and at relapse of acute lymphoblastic leukemia (ALL). Leukemia 1997; 11: 971-978.
15. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997; 11 (Suppl. 1): S7-S11.
16. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999; 59: 3730-3740.
17. Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 1996; 56: 973-977.
18. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841.
19. Chim CS, Liang R, Tam CYY, Kwong YL. Methylation of p15 and p16 genes in Acute Promyelocytic Leukemia: diagnostic and prognostic significance. J Clin Oncol 2001; 19: 2033-2040.
20. Chim CS, Tam CYY, Liang R, Kwong YL. Methylation of p15 and p16 genes in Adult Acute Leukemia: lack of prognostic significance. Cancer 2001; 91: 2222-2229.
21. Wong IHN, Ng MHL, Huang DP, Lee JCK. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000; 95: 1942-1949.
22. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998; 91: 2985-2990.
23. Aggerholm A, Guldberg P, Hokland M, Hokland P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 1999; 59: 436-441.
24. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997; 57: 832-839.
25. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500-2506.
26. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-2984.
27. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTSI) in B-cell and T-cell lymphomas. Blood 1999; 94: 1773-1781.
28. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845-859.
29. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HICI hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997; 57: 1678-1681.
30. Corn PG, Kuerbitz SJ, van-Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999; 59: 3352-3356.
31. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999; 94: 1113-1120.
32. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood 2000; 95: 3208-3213.
33. Issa JP, Kantarjian H, Mohan A, et al. Methylation of the ABLI promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 1999; 93: 2075-2080.
34. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
35. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
36. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
37. Sill H, Aguiar CT, Schmidt H, Hochhaus A, Goldman JM, Cross NC. Mutational analysis of the p15 and p16 genes in acute leukaemias. Br J Haematol 1996; 92: 681-683.
38. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999; 94: 2445-2451.
39. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 1997; 94: 5302-5307.
40. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94: 2551-2556.
41. Chim JC, Coyle LA, Yaxley JC, et al. Investigation of minimal residual disease by the use of a semi quantitative multi-step test combination in ALL. Br J Haematol 1996; 92: 104-115.
42. Foroni L, Coyle LA, Papioannou M, et al. Molecular detection of minimal residual disease in adult and childhood ALL reveals differences in treatment responses. Leukemia 1997; 11: 1732-1741.
43. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood 1995; 85: 1416-1434.
44. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 1999; 59: 3899-3903.
45. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-2718.
46. Orlow I, Drobnjak M, Zhang ZF, et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst 1999; 91: 73-79.
47. Li Q, Kopecky KJ, Mohan A, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5: 1077-1084.
48. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78-85.
49. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586.
50. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet 2000; 24: 132-138.